NSE-apoE4, but not GFAP-apoE4, mice have decreased spine density in the auditory cortex at 19–21 months of age. by Sachi Jain (108277)

Rab9a overexpression decreases phagocytosis of <i>E</i>. <i>coli</i> and <i>Salmonella</i>. by Elsa Seixas (76018)

Cyclooxygenase inhibition decreases immune control of fungal germination and invasive hyphal growth. by Savini Thrikawala (5690510)

FGF10 dose dependency of the cellular response in E13.5 (black) and E14.5 (blue) epithelium. by Hisako Takigawa-Imamura (3175320)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

Effects of A1AR expression on response to hypoxia at E9.5 and E12.5. by Daniela L. Buscariollo (140729)

“…In hypoxia, E9.5 A1AR +/− heart rates decreased then returned to baseline levels following recovery in room air (p<0.0001 and p<0.01, for t = 25 and t = 40 compared to t = 0, respectively). …”

The m⁶A peak of 3’UTR of TLR4 mRNA decreases significantly in METTL14-knockdown PK-15 cells. by Jing Chen (4762)

Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

“…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”

<i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort by Mindi J. TenNapel (679433)

Table 1_Subjective spatial orientation discomfort is associated with decreased real-world spatial performance and lower cognitive function.docx by Johannes Gerb (10287758)

Simultaneous downregulation of LIFR and OSMR decreases IL-6 and MCP-1 release and prevents STAT1 and STAT3 phosphorylation. by Danielle van Keulen (5807507)

T0 treatment significantly decreased soluble Aβ oligomers, but not amyloid plaque pathology in APP/E4/Abca1^+/- mice. by Alexis Y. Carter (3798223)

“…N = 5–6 mice per group. N.S., not significant. <b>E,</b> T0 treatment significantly decreases Aβ oligomers in APP/E4/Abca1^+/- mice. …”

CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i>^<i>ECKO</i> mice and lesions in the retina of <i>Ccm2</i>^<i>ECKO</i> mice. by Jia Li (160557)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)